Bannerbild German Brest Group - Forschung

Übersicht über Originalarbeiten von 2011

Mitglieder der German Breast Group veröffentlichten im Jahr 2011 folgende Originalarbeiten:

Guo X, Loibl S, Untch M, Möbus V, Schwedler K, Fasching P.A. Barinoff J, Holms F, Thomssen C, Zahm D-M, Kreienberg R, Hauschild M, Eidtmann H, Tauchert S, Mehta K, von Minckwitz G, for the German Breast Group and AGO-B Study Group: Re-challenging taxanes in recurrent breast cancer in patients treated with (neo-) adjuvant taxane-based therapy. Breast Care 6:279-283, 2011

Denkert C, Sinn BV, Issa Y, Maria Müller B, Maisch A, Untch M, von Minckwitz G, Loibl S: Prediction of Response to Neoadjuvant Chemotherapy: New Biomarker Approaches and Concepts. Breast Care (Basel) 6(4):265-272, 2011

Loibl S, Doering G, Müller L, Grote-Metke A, Müller R, Tomé O, Wiest W, Maisch A, Nekljudova V, von Minckwitz G: Multicenter Phase II Study with Weekly Bendamustine and Paclitaxel as First- or Later-Line Therapy in Patients with Metastatic Breast Cancer: RiTa II Trial. Breast Care 6:457-461, 2011

Alvarez RH, Guarneri V, Icli F, Johnston S, Khayat D, Loibl S, Martin M, Zielinski C, Conte P, Hortobagyi GN: Bevacizumab Treatment for Advanced Breast Cancer. Oncologist. 2011 Oct 5. [Epub ahead of print]

Loibl S, Müller BM, von Minckwitz G, Schwabe M, Roller M, Darb-Esfahani S, Ataseven B, du Bois A, Fissler-Eckhoff A, Gerber B, Kulmer U, Alles JU, Mehta K, Denkert C: Androgen receptor expression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapy. Breast Cancer Res Treat. 130(2):477-87, 2011

von Minckwitz G, Loibl S, Jackisch C, Paepke S, Nestle-Kraemling C, Lux MP, Maass N, Schmutzler R, du Bois A, Wallwiener D, Vescia S, Budischewski K, Kaufmann M: The GISS Trial: a Phase II Prevention Trial of Screening Plus Goserelin, Ibandronate, versus Screening Alone in Premenopausal Women at Increased Risk of Breast Cancer. Cancer Epidemiol Biomarkers Prev. 20(10):2141-9, 2011

Untch M, Fasching PA, Konecny GE, Hasmüller S, Lebeau A, Kreienberg R, Camara O, Müller V, du Bois A, Kühn T, Stickeler E, Harbeck N, Höss C, Kahlert S, Beck T, Fett W, Mehta KM, von Minckwitz G, Loibl S: Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups. J Clin Oncol. 29(25):3351-7, 2011

von Minckwitz G, Schwedler K, Schmidt M, Barinoff J, Mundhenke C, Cufer T, Maartense E, de Jongh FE, Baumann KH, Bischoff J, Harbeck N, Lück HJ, Maass N, Zielinski C, Andersson M, Stein RC, Nekljudova V, Loibl S; On behalf of the GBG 26/BIG 03-05 study group and participating investigators: Trastuzumab beyond progression: Overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer. Eur J Cancer. 47(15):2273-2281, 2011

Baumann K, Pfisterer J, Wimberger P, Burchardi N, Kurzeder C, du Bois A, Loibl S, Sehouli J, Huober J, Schmalfeldt B, Vergote I, Lück HJ, Wagner U: Intraperitoneal treatment with the trifunctional bispecific antibody Catumaxomab in patients with platinum-resistant epithelial ovarian cancer: A phase IIa study of the AGO Study Group. Gynecol Oncol. 123(1):27-32, 2011

Denkert C, Darb-Esfahani S, Loibl S, Anagnostopoulos I, Jöhrens K: Anti-cancer immune response mechanisms in neoadjuvant and targeted therapy. Semin Immunopathol. 33(4):341-51, 2011

von Minckwitz G, Darb-Esfahani S, Loibl S, Huober J, Tesch H, Solbach C, Holms F, Eidtmann H, Dietrich K, Just M, Clemens MR, Hanusch C, Schrader I, Henschen S, Hoffmann G, Tiemann K, Diebold K, Untch M, Denkert C: Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer-results from the GeparQuattro study (GBG 40). Breast Cancer Res Treat. 2011 Jun 12. [Epub ahead of print]

Gerber B, von Minckwitz G, Stehle H, Reimer T, Felberbaum R, Maass N, Fischer D, Sommer H, Conrad B, Ortmann O, Fehm T, Rezai M, Mehta K, Loibl S on behalf of the German Breast Group Investigators: Effect of LHRH agonists on ovarian function after modern-type adjuvant breast cancer chemotherapy : The GBG 37 "ZORO" study. J Clin Oncol. 29(17):2334-41, 2011

von Minckwitz G, Müller M.B, Loibl S, Budczies J Hanusch C, Darb-Esfahani S, Hilfrich J, Weiss E, Huober J, Blohmer JU, du Bois A, Zahm DM, Khandan F, Hoffmann G, Gerber B, Eidtmann H, Fend F, Dietel M, Mehta K, Denkert C for GBG investigators: Cytoplasmic Poly(Adenosine Diphosphate-Ribose) Polymerase Expression Is Predictive and Prognostic in Patients With Breast Cancer Treated With Neoadjuvant Chemotherapy. J Clin Oncol. 29(16):2150-7, 2011

Loibl S, Skacel T, Nekljudova V, Lück HJ, Schwenkglenks M, Brodowicz T, Zielinski C, von Minckwitz G: Evaluating the impact of Relative Total Dose Intensity (RTDI) on patients' short and long-term outcome in taxane- and anthracycline-based chemotherapy of metastatic breast cancer– a pooled analysis. BMC Cancer. 12;11:131, 2011

Hilvo M, Denkert C, Lehtinen L, Muller B, Brockmoller S, Seppanen-Laakso T, Budczies J, Bucher E, Yetukuri L, Castillo S, Berg E, Nygren H, Sysi-Aho M, Griffin JL, Fiehn O, Loibl S, Richter-Ehrenstein C, Radke C, Hyotylainen T, Kallioniemi O, Iljin K, Oresic M: Novel theranostic opportunities offered by characterization of altered membrane lipid metabolism in breast cancer progression. Cancer Res. 71(9):3236-3245, 2011

Untch M, Fasching P.A, Konecny G, von Koch F, Conrad U, Fett W, Kurzeder C, Lück HJ, Stickeler E, Urbaczyk H, Liedtke B, Salat C, Harbeck N, Müller V, Schmidt M, Hasmüller S, Lenhard M, Schuster T, Nekljudova V, Loibl S, von Minckwitz G on behalf of the AGO PREPARE investigators: PREPARE trial. A randomized phase III trial comparing preoperative, dose-dense, dose intensified chemotherapy with epirubicin, paclitaxel and CMF versus a standard dosed epirubicin / cyclophosphamide followed by paclitaxel ± darbepoetin alfa in primary breast cancer – results at the time of surgery. Ann Oncol. 22(9):1988-98, 2011

Untch M, von Minckwitz G, Konecny G, Conrad U, Fett W, Kurzeder C, Lück HJ, Stickeler E, Urbaczyk H, Liedtke B, Beckmann M.W, Salat C, Harbeck N, Müller M, Schmidt M, Hasmüller S, Lenhard M, Nekljudova V, Loibl S, Fasching P.A, on behalf of the AGO PREPARE investigators: PREPARE trial. A randomized phase III trial comparing preoperative, dose-dense, dose intensified chemotherapy with epirubicin, paclitaxel and CMF versus standard dose and schedule of epirubicin / cyclophosphamide followed by paclitaxel without CMF ± darbepoetin alfa in primary breast cancer – outcome on prognosis. Ann Oncol. 22(9):1999-2006, 2011

Noske A, Loibl S, Darb-Esfahani S, Roller M, Kronenwett R, Müller BM, Steffen J, von Toerne C, Wirtz R, Baumann I, Hoffmann G, Heinrich G, Grasshoff ST, Ulmer HU, Denkert C, von Minckwitz G: Comparison of different approaches for assessment of HER2 expression on protein and mRNA level: prediction of chemotherapy response in the neoadjuvant GeparTrio trial (NCT00544765). Breast Cancer Res Treat. 126(1):109-17, 2011

Loibl S, Lintermans A, Dieudonné AS, Neven P: Management of menopausal symptoms in breast cancer patients. Maturitas. 68(2):148-54, 2011

von Minckwitz G, Untch M, Nüesch E, Loibl S, Kaufmann M, Kümmel S, Fasching PA, Eiermann W, Blohmer JU, Costa SD, Mehta K, Hilfrich J, Jackisch C, Gerber B, du Bois A, Huober J, Hanusch C, Konecny G, Fett W, Stickeler E, Harbeck N, Müller V, Jüni P: Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials. Breast Cancer Res Treat. 125(1):145-56, 2011

Loibl S, Mueller V, von Minckwitz G, Conrad B, Koehne CH, Kremers S, Forstbauer H, Linder M, Nekljudova V, Moebus V; On behalf of the GBG/AGO/NOGGO study groups: Comparison of pegfilgrastim on day 2 vs. day 4 as primary prophylaxis of intense dose-dense chemotherapy in patients with node-positive primary breast cancer within the prospective, multi-center GAIN study: (GBG 33). Support Care Cancer. 19(11):1789-95, 2011

Kontakt

Hilal Gökgöz
Tel.: +4961027480-223
Fax: +4961027480-129
E-Mail: Pblctnsgbgd

GBG Forschungs GmbH
Martin-Behaim-Str. 12 | 63263 Neu-Isenburg | Fax +49 6102 7480-440

+49 6102 7480-0 | nfGBGd